Posted on 3/28/19
EyePoint Pharmaceuticals Proposes Public Offering of Common Stock
WATERTOWN, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today . . .
Posted on 3/27/19
Avant-garde Health and Titanium Healthcare Partner
Avant-garde Health and Titanium Healthcare, LLC have partnered to enable health systems to improve patient care, as part of the Centers for Medicare & Medicaid Services' . . .
Posted on 3/27/19
Fresenius Medical Care North America Renews Partnership with National Kidney Foundation
For the second year, Fresenius Medical Care North America (FMCNA), the largest provider of dialysis products and services, will serve as National Presenting Sponsor for the . . .
Posted on 3/27/19
Syndax Announces $26.2 Million Offering of Common Stock and Warrants
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement . . .
Posted on 3/27/19
Juvenescence Capitalizes BYOMass With up to $6.5 Million
Juvenescence Ltd, a biopharmaceutical company focused on treating aging and age-related disease, is pleased to announce its latest equity investment in BYOMass Inc.,
Posted on 3/27/19
Biogen Should Reconsider Its Strategic Shift To Neuro-Degenerative Disorders
SummaryBiogen has its origin in multiple sclerosis (MS'), with MS revenues peaking in 2017.Biogen dropped a molecule amiselimod that could have competed with Novartis' MS blockbuster . . .
Posted on 3/27/19
Biogen's Bad News for Everyone
In this episode of Motley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent . . .
Posted on 3/26/19
Harvard Bioscience To Showcase Products at Experimental Biology 2019
All Three Commercial Units to Be Represented Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance . . .
Posted on 3/26/19
Selecta Biosciences Announces New Employment Inducement Grant
WATERTOWN, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies . . .
Posted on 3/26/19
TCR2 Therapeutics Announces Collaboration With Cell and Gene Therapy Catapult
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today . . .
Posted on 3/26/19
Archway Health Announces Partnership With A-Rated Insurance Carrier
BOSTON--(BUSINESS WIRE)--As healthcare migrates from fee-for-service payment models to value-based care, providers increasingly seek solutions that offer them protection against losses within two-sided, risk-based arrangements. Today, . . .
Posted on 3/26/19
ReviveMed Receives Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReviveMed is proud to announce that they are the recipient of the North American AI-Driven Next-Generation Metabolomics Technology Innovation Award from Frost & Sullivan . . .
Posted on 3/26/19
Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers Clues
SummaryUncertainty around the proposed Bristol-Myers/Celgene merger remains elevated as several institutional investors lobby against the deal.It's nearly impossible to discern the outcome by reading headlines; everyone . . .
Posted on 3/26/19
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
SummaryProposed deal deeply undervalues Celgene, and BMS admits it.Celgene’s pipeline is about to turn a corner with potentially 5 product launches in the next 2 years.Bristol-Myers . . .
Posted on 3/26/19
Biogen - Pipeline Setback Looks To Create An Opportunity
SummaryBiogen has seen a huge setback in its pipeline as its Alzheimer's candidate has flunked.Despite the setback, I believe the risk-reward has changed for the good . . .
Posted on 3/26/19
Akebia Therapeutics: Still A Buy Post-Merger
SummaryAKBA’s stock price dipped quite a bit from June to December 2018 on relatively no material news.The start of 2019 has seen a nice recovery, but . . .
Posted on 3/26/19
SilverCloud Health's Digital Mental Health Platform Selected for NIMH & Washington University Research Study
SilverCloud Health, a global provider of clinically validated digital mental healthcare solutions for health systems and payers, announced today a national research partnership with the Washington . . .
Posted on 3/25/19
SEQENS North America Wins Big at 2019 Life Science Leader Magazine CMO Leadership Awards
NEWBURYPORT, Mass.--(BUSINESS WIRE)--SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical . . .
Posted on 3/25/19
Curis Sells Portion of Erivedge Royalties To Oberland Capital For Up To $135.7 Million
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer
Posted on 3/25/19
Bristol-Myers Squibb Board Sends Letter to Shareholders Regarding Merger With Celgene
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with . . .
Posted on 3/25/19
2019’s Best & Worst States for Doctors – WalletHub Study
Doctors are among the highest-paid and most educated professionals in the U.S. In fact, “physician” was the highest-paid job type in 2018, with a median base . . .
Posted on 3/25/19
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
Rare diseases have proven to be gold mines for Vertex Pharmaceuticals (NASDAQ:VRTX)and Regeneron Pharmaceuticals (NASDAQ:REGN). Vertex's market cap of nearly $47 billion and Regeneron's market cap . . .
Posted on 3/25/19
Is Biogen a Bad-News Buy Now?
Wise drug developers say only fools rush in, but Biogen (NASDAQ:BIIB) couldn't help falling in love with early data for experimental Alzheimer's drug aducanumab about four . . .
Posted on 3/25/19
2 Biotech Takeout Targets Perfect for Biogen
Biogen (NASDAQ:BIIB) recently suffered a brutal stock market beating after its big Alzheimer's candidate failed to make a difference for patients with early signs of the . . .
Posted on 3/25/19
resTORbio Closes Public Offering of Common Stock
BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or . . .

